Postoperative [I-125] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland With associated risk factors

Background. This retrospective study was undertaken to analyze data from patients receiving iodine-125 ([I-125]) seed brachytherapy postoperatively for the treatment of acinic cell carcinoma (ACC) of the parotid gland along with the following risk factors: residual tumor, recurrent tumor, facial nerve invasion, positive resection margins, advanced tumor stage, or tumor spillage. Patients and methods. Twenty-nine patients with ACC (17 females, 12 males; age range, 13-73 years; median age, 37.3 years) were included. Median follow-up was 58.2 months (range, 14-122 months). Patients received [I-125] seed brachytherapy (median actuarial D90, 177 Gy) 3-41 days (median, 14 days) following surgery. Radioactivity was 18.5-33.3 MBq per seed, and the prescription dose was 80-120 Gy. Results. The 3-, 5-, and 10-year rates of local control were 93.1, 88.7, and 88.7%, respectively; overall survival was 96.6, 92, and 92%; disease-free survival was 93.1, 88.4, and 88.4%; and freedom from distant metastasis was 96.6, 91.2, and 91.2%. Lymph node metastases were absent in all patients, although two patients died with distant metastases. Facial nerve recovery was quick, and no severe radiotherapy-related complications were noted. Recurrence history, local recurrence, and distant metastasis significantly affected overall survival. Conclusion. Postoperative [I-125] seed brachytherapy is effective in treating ACC and has minor complications. Patients with a history of recurrence showed poor prognosis and were more likely to experience disease recurrence and develop metastases.OncologyRadiology, Nuclear Medicine & Medical ImagingSCI(E)PubMed0ARTICLErszhang@126.com111008-101419